SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-150395
Filing Date
2024-05-30
Accepted
2024-05-30 16:33:56
Documents
13
Period of Report
2024-05-30
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d806070d8k.htm   iXBRL 8-K 23650
  Complete submission text file 0001193125-24-150395.txt   148212

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA syre-20240530.xsd EX-101.SCH 2833
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE syre-20240530_lab.xml EX-101.LAB 18758
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syre-20240530_pre.xml EX-101.PRE 11699
16 EXTRACTED XBRL INSTANCE DOCUMENT d806070d8k_htm.xml XML 3766
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 241006004
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)